This story was originally published July 22.

Cancer Research UK has selected Illumina as a preferred service provider for whole-genome sequencing of cancer genomes as part of its contribution to the International Cancer Genome Consortium.

Illumina's sequencing services will first be applied toward prostate and esophageal cancers and will include whole-genome sequencing on the HiSeq 2000 of up to 1,500 samples over the next three years on both tumor and normal genomes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.